LRP-8 binding dual variable domain immunoglobulin proteins

1. A dual variable domain immunoglobulin (DVD-Ig) binding protein capable of binding low density lipoprotein receptor-related protein 8 (LRP-8), comprising a heavy chain variable domain comprising a set of three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3), and a light chain variable domain comprising a set of three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3), wherein the heavy chain CDRs are:

(a) CDR-H1: RFTFSNX 1 GMS (SEQ ID NO: 9), wherein X 1 is F or Y, or GFTVSDYYMA (SEQ ID NO: 53);

(b) CDR-H2: TISSGGRYTYYPDX 2 VKG (SEQ ID NO: 10), wherein X 2 is S or H, or SISYEGSSTYYGDSVKG (SEQ ID NO: 54); and

(c) CDR-H3: DYLYAMDY (SEQ ID NO: 46) or PLRYYGYNYRFAY (SEQ ID NO: 55), and the light chain CDRs are:

(d) CDR-L1: RSSQSLVYSX 3 X 4 NTYLH (SEQ ID NO: 47), wherein X 3 is N, T, R, W or P, and wherein X 4 is G, E, L or K, or KASQNIHKNLD (SEQ ID NO: 56);

(e) CDR-L2: KVSNRFS (SEQ ID NO: 48) or YTDNLQT (SEQ ID NO: 57); and

(f) CDR-L3: SQSTHVPLT (SEQ ID NO: 49) or YQYNSGPT (SEQ ID NO: 58).

2. The DVD-Ig binding protein of claim 1 , wherein the set of three heavy chain CDRs is selected from the group consisting of:

(a) SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90;

(b) SEQ ID NO: 91, SEQ ID NO: 89, SEQ ID NO: 90;

(c) SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 46;

(d) SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 46; and

(e) SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109;

wherein the set of three light chain CDRs is selected from the group consisting of:

(i) SEQ ID NO: 157, SEQ ID NO: 48, SEQ ID NO: 49;

(ii) SEQ ID NO: 158, SEQ ID NO: 48, SEQ ID NO: 49;

(iii) SEQ ID NO: 159, SEQ ID NO: 48, SEQ ID NO: 49;

(iv) SEQ ID NO: 160, SEQ ID NO: 48, SEQ ID NO: 49;

(v) SEQ ID NO: 161, SEQ ID NO: 48, SEQ ID NO: 49;

(vi) SEQ ID NO: 162, SEQ ID NO: 48, SEQ ID NO: 49;

(vii) SEQ ID NO: 163, SEQ ID NO: 48, SEQ ID NO: 49;

(viii) SEQ ID NO: 164, SEQ ID NO: 48, SEQ ID NO: 49; and

(xi) SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58.

3. The DVD-Ig binding protein of claim 1 , wherein:

(a) the heavy chain variable domain comprises an amino acid sequence of EVQLVESGGDLVKPGGSLKLSCAASRFTFSNFGMSWVRQTPDKRLEWV ATISSGGRYTYYPDX 1 VKGRFTISRDNAKNTLYLQMSSLRSEDTAMYY CARDYLYAMDYWGQGTSVTVSS (SEQ ID NO: 50), or EVQLVESGGDLVKPGGSLKLSCAASRFTFSNYGMSWVRQTPDKRLEWV ATISSGGRYTYYPDX 1 VKGRFTISRDNAKNTLYLQMSSLRSEDTAMYY CARDYLYAMDYWGQGTSVTVSS (SEQ ID NO: 51), wherein X 1 is S or H; or EVQLVESGGGINQPGRSLKLSCAASGFTVSDYYMAWVRQAPKKGLEWV ASISYEGSSTYYGDSVKGRFTISRDNAKSILYLQMNSLRSEDTATYYC ARPLRYYGYNYRFAYWGQGTLVTVSS (SEQ ID NO: 59), and/or

(b) the light chain variable domain comprises an amino acid sequence of DVVMTQTPLSLPVSLGDQASISCRSSQSLVYSX 2 X 3 NTYLHWYLQKPG QSPKVLMYKVSNRFSGVSDRFSGSGSGTDFTLKISRVEAEDLGVYFCS QSTHVPLTFGAGTKLELK (SEQ ID NO: 52) wherein X 2 is N, T, R, W or P and X 3 is G, E, L or K; or DIQMSQSPPVLSASVGDRVILSCKASQNIHKNLDWYQQKHGEAPKLLI IYYTDNLQTGIPSRFSGSGSGTDYTLTISSLQPEDVATYYCYQYNSGP TFGAGTKLELQ (SEQ ID NO: 60).

4. The DVD-Ig binding protein of claim 1 , wherein the binding protein comprises a heavy chain CDR set of:

(a) CDR-H1: RFTFSNYGMS (SEQ ID NO: 92);

(b) CDR-H2: TISSGGRYTYYPDSVKG (SEQ ID NO: 93); and

(c) CDR-H3: DYLYAMDY (SEQ ID NO: 46),

and a light chain CDR set of:

(d) CDR-L1: RSSQSLVYSNGNTYLH (SEQ ID NO: 157);

(e) CDR-L2: KVSNRFS (SEQ ID NO: 48); and

(f) CDR-L3: SQSTHVPLT (SEQ ID NO: 49).

5. The DVD-Ig binding protein of claim 1 , wherein the binding protein comprises

(a) a heavy chain variable domain of:

(SEQ ID NO: 62)

EVQLVESGGDLVKPGGSLKLSCAARSRFTFSNYGMSWVRQTPDKRLEWVA

TISSGGRYTYYPDSVKGRFTISRDNAKNTLYLQMSSLRSEDTAMYYCARD

YLYAMDYWGQGTSVTVSS;

and a light chain variable domain of:

(SEQ ID NO: 63)

DVVMTQTPLSLPVSLGMASISCRSSQSLVYSNGNTYLHWYLQKPGOSPKV

LMYKVSNRFSGVSDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPL

TFGAGTKLELK;

(b) a heavy chain variable domain of:

(SEQ ID NO: 59)

EVQLVESGGGLVQPGRSLKLSCAAS GFTVSDYYMA WVRQAPKKGLEWVA S

ISYEGSSTYYGDSVKG RFTISRDNAKSILYLQMNSLRSEDTATYYCAR PL

RYYGYNYRFAY WGQGTLVTVSS;

and a light chain variable domain of:

(SEQ ID NO: 60)

DIQMSQSPPVLSASVGDRVTLSC KASQNIHKNLD WYQQKHGEAPKLLIY Y

TDNLQT GIPSRFSGSGSGTDYTLTISSLQPEDVATYYC YQYNSGPT FGAG

TKLELQ;

(c) a heavy chain variable domain of:

(SEQ ID NO: 61)

EVQLVESGGDLVKPGGSLKLSCAAS RFTFSNFGMS WVRQTPDKRLEWVA T

ISSGGRYTYYPDSVKG RFTISRDNAKNTLYLQMSSLRSEDTAMYYCAR DY

LYAMDY WGQGTSVTVSS;

and

and

a light chain variable domain of:

(SEQ ID NO: 63)

DVVMTQTPLSLPVSLGDQASISC RSSQSLVYSNGNTYLH WYLQKPGQSPK

VLMY KVSNRFS GVSDRFSGSGSGTDFTLKISRVEAEDLGVYFC SQSTHVP

LT FGAGTKLELK.

6. The DVD-Ig binding protein of claim 1 , wherein the binding protein is also capable of binding a second antigen target in the brain or spinal cord other than LRP-8.

7. The DVD-Ig binding protein of claim 1 , wherein the binding protein binds human LRP-8 and is cross-reactive with at least one of cynomolgus monkey, rat, and mouse LRP-8.

8. The DVD-Ig binding protein of claim 1 , wherein the binding protein

(a) binds to human LRP-8 with an EC50 of at most about 2.62 nM, or at most about 2.29 nM, or at most about 0.88 nM, or at most about 0.24 nM;

(b) undergoes endocytosis by HEK293 cells expressing LRP-8 at a rate between 1.5 and 2.5 times the endocytosis of control IgG into HEK293 cells expressing LRP-8;

(c) undergoes transcytosis across a Caco-2 cell monolayer expressing LRP-8 at a rate between 1.5 and 2.0 times the transcytosis of control IgG across a Caco-2 cell monolayer expressing LRP-8; and/or

(d) is able to cross the blood-brain barrier after binding to LRP-8.

9. The DVD-Ig binding protein of claim 1 , further comprising a wild-type human lambda or kappa light chain constant region, and a wild-type human IgG1 heavy chain constant region or a variant of a human IgG1 heavy chain constant region.

10. The DVD-Ig binding protein of claim 9 , wherein the variant comprises a leucine (L) to alanine (A) mutation at amino acid positions 234 and 235 of human IgG1.

11. The DVD-Ig binding protein of claim 1 , further comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, or a variant thereof.

12. The DVD-Ig binding protein of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence at least about 80%, 90%, 95%, or 98% homologous to any of those selected from SEQ ID NOs: 59, 61, 62, and 70-72, and/or wherein the light chain variable domain comprises an amino acid sequence at least about 80%, 90%, 95%, or 98% homologous to any of those selected from SEQ ID NOs: 60, 63, and 133-142.

13. The DVD-Ig binding protein of claim 1 , wherein the heavy chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 59, 61, 62, and 70-72 and/or wherein the light chain variable domain comprises an amino acid sequence selected from SEQ ID NOs: 60, 63, and 133-142.

14. A conjugate comprising the DVD-Ig binding protein of claim 1 and a second agent, wherein the second agent acts on the nervous system and is capable of being transported across the blood-brain barrier when the conjugate binds to LRP-8.

15. A pharmaceutical composition comprising the DVD-Ig binding protein of claim 1 , and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 , further comprising at least one additional agent, wherein the additional agent acts on the nervous system, or is an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, a detectable label or reporter, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

17. A method of detecting the presence, amount, or concentration of LRP-8 or a fragment of LRP-8 in a test sample by an immunoassay, comprising contacting the test sample with at least one binding protein and at least one detectable label, and wherein the at least one binding protein comprises the DVD-Ig binding protein of claim 1 .

18. A dual variable domain immunoglobulin (DVD-Ig) binding protein that binds to human low density lipoprotein receptor-related protein 8 (LRP-8) at an epitope comprising amino acid residues 47-66 of human LRP-8 (SEQ ID NO:1).

19. The DVD-Ig binding protein of claim 18 , wherein the binding protein binds to human LRP-8 at an epitope comprising amino acid residues 47(C), 52(F), 56(N), 59(C), 60(I), 64(W), and 66(C) of human LRP-8 (SEQ ID NO:1).

20. A monoclonal antibody that binds to human low density lipoprotein receptor-related protein 8 (LRP-8) at an epitope comprising amino acid residues 47-66 of human LRP-8 (SEQ ID NO:1).

21. The antibody of claim 20 , wherein the antibody binds to human LRP-8 at an epitope comprising amino acid residues 47(C), 52(F), 56(N), 59(C), 60(I), 64(W), and 66(C) of human LRP-8 (SEQ ID NO:1).

22. A monoclonal antibody capable of binding low density lipoprotein receptor-related protein 8 (LRP-8), comprising a heavy chain variable domain comprising a set of three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3), and a light chain variable domain comprising a set of three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3), wherein the heavy chain CDRs are:

(a) CDR-H1: RFTFSNX 1 GMS (SEQ ID NO: 9), wherein X 1 is F or Y, or GFTVSDYYMA (SEQ ID NO: 53);

(b) CDR-H2: TISSGGRYTYYPDX 2 VKG (SEQ ID NO: 10), wherein X 2 is S or H, or SISYEGSSTYYGDSVKG (SEQ ID NO: 54); and

(c) CDR-H3: DYLYAMDY (SEQ ID NO: 46) or PLRYYGYNYRFAY (SEQ ID NO: 55),

and the light chain CDRs are:

(d) CDR-L1: RSSQSLVYSX 3 X 4 NTYLH (SEQ ID NO: 47), wherein X 3 is N, T, R, W or P, and wherein X 4 is G, E, L or K, or KASQNIHKNLD (SEQ ID NO: 56);

(e) CDR-L2: KVSNRFS (SEQ ID NO: 48) or YTDNLQT (SEQ ID NO: 57); and

(f) CDR-L3: SQSTHVPLT (SEQ ID NO: 49) or YQYNSGPT (SEQ ID NO: 58).

23. The antibody of claim 22 , wherein the antibody comprises a heavy chain CDR set of:

(a) CDR-H1: RFTFSNYGMS (SEQ ID NO: 92);

(b) CDR-H2: TISSGGRYTYYPDSVKG (SEQ ID NO: 93); and

(c) CDR-H3: DYLYAMDY (SEQ ID NO: 46),

and a light chain CDR set of:

(d) CDR-L1: RSSQSLVYSNGNTYLH (SEQ ID NO: 157);

(e) CDR-L2: KVSNRFS (SEQ ID NO: 48); and

(f) CDR-L3: SQSTHVPLT (SEQ ID NO: 49).

24. The antibody of claim 22 , wherein the antibody is a humanized antibody.

25. The antibody of claim 23 , wherein the antibody is a humanized antibody.